ChemotherapyPhase 3 trialInvestigational

Decitabine

How it works

Interferes with DNA synthesis, preventing cancer cell growth and division.

Cancer types

LeukemiaMDS

Efficacy

In clinical trials, around 50% of patients with MDS achieved a complete or partial response.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Testing Oral Decitabine and Cedazuridine in Cancer Patients with Kidney IssuesLeukemiaphase-1Source →
Testing Oral Decitabine and Cedazuridine in Cancer Patients with Liver ProblemsLeukemiaphase-1Source →
Genetically Modified T Cells and Decitabine in Treating Ovarian CancerOvarian Cancerphase-1Source →
Testing New Combination Therapy for Blood CancersLeukemiaphase-1Source →
Testing Combination Therapy for Advanced LeukemiaLeukemiaphase-1Source →
Cancer Gene Methylation Linked to Poor Prognosis in LeukemiaLeukemialab-studyHypermethylation of the miR-34c CpG island correlated with shorter overall survival.Source →
Researchers Identify Gene Mutation Linked to Resistance to Cancer TreatmentLeukemialab-studySource →
Understanding How Decitabine Affects Cancer CellsLeukemialab-studySource →
Woman develops rare skin condition after leukemia treatmentLeukemiaobservationalSource →
Elderly AML Patient Achieves Long Remission with Decitabine and Retinoic AcidLeukemiaphase-2The patient attained a complete hematologic and cytogenetic remission with 3.7 years survival after 30 treatment cycles.Source →
Combining Cancer Drugs May Improve Treatment for Breast and Ovarian CancersOvarian Cancerlab-studyCell proliferation was inhibited by 48-70%, and Annexin V positivity was 42-59% in all cell lines exposed to the three-drug combinations.Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.